THE INTERIM EXPERTS’ COUNCIL RESOLUTION ON THE EMPA-REG OUTCOME TRIAL ISSUES

THE INTERIM EXPERTS’ COUNCIL RESOLUTION ON THE EMPA-REG OUTCOME TRIAL ISSUES

The interdisciplinary interim experts’ council on March 3, 2016 in Moscow have considered the EMPA-REG OUTCOME trial results and suggested a number of propositions and recommendations on further empagliflozin’s cardiovascular effects investigation and its clinical application in patients with type 2...

Full description

Saved in:
Bibliographic Details
Main Authors: M. V. Shestakova, S. A. Boytsov, O. M. Drapkina, T. Yu. Demidova, H. Drexel, M. B. Antsiferov, N. A. Petunina, N. A. Chernikova, V. Yu. Kalashnikov, T. P. Bardymova, V. K. Protasov, A. Yu. Babenko, L. A. Ruyatkina, V. V. Klimontov, V. V. Salukhov, V. V. Fadeev, Yu. A. Karpov
Format: Article
Language:English
Published: Столичная издательская компания 2016-05-01
Series:Рациональная фармакотерапия в кардиологии
Subjects:
empagliflozin
type 2 diabetes mellitus
cardiovascular morbidity and mortality
empa-reg outcome trial
Online Access:https://www.rpcardio.online/jour/article/view/1237
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The interdisciplinary interim experts’ council on March 3, 2016 in Moscow have considered the EMPA-REG OUTCOME trial results and suggested a number of propositions and recommendations on further empagliflozin’s cardiovascular effects investigation and its clinical application in patients with type 2 diabetes at high cardiovascular risk.
ISSN:1819-6446
2225-3653

Similar Items